about
Interventions for the management of fatigue in adults with a primary brain tumourAntiepileptic drugs for preventing seizures in people with brain tumorsAdult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experienceFacing the future of brain tumor clinical researchSeizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Personal health records as portal to the electronic medical record.Venous thromboembolism (VTE) and glioblastoma.Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.Pregnancy and glial brain tumorsPredictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007Glial tumors--new approaches in chemotherapy.Exploring the Cancer Experiences of Young Adults in the Context of Stem Cell TransplantationIDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials.Primary brain tumors and posterior reversible encephalopathy syndromeImpact of recall period on primary brain tumor patient's self-report of symptoms.Personal health records, symptoms, uncertainty, and mood in brain tumor patients.C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.Central nervous system toxicity from cancer treatment.Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-ChronicSymptom clusters in oncology patients and implications for symptom research in people with primary brain tumors.Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory.Hope and mood changes throughout the primary brain tumor illness trajectory.The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptomsReport of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapyBiology and management of ependymomas.Increased intracranial pressure.Use of complementary and alternative medical therapy by patients with primary brain tumors.Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Head's up on the treatment of malignant glioma patients.Brain tumor symptoms as antecedents to uncertainty: an integrative review.Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience.Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.Psycho-oncology.Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
P50
Q24185905-BA674CBB-A046-460D-9AEE-482B6CD243D8Q24243118-1E6C0683-8E3C-4A46-934A-F63F6AA1329CQ24607694-8A0C2787-3FB2-4542-8BA2-38904BC71F1BQ27013296-FF63532D-663C-48FD-9D25-D30D8AFAF0CFQ30275879-C01F2807-A906-4785-A7E3-CE18AF91756AQ30417015-AF5F9E73-91EF-4D2E-B19F-78544C4487A6Q30486669-1B0639A2-59C2-496E-B7B9-96C6C2902522Q33422929-881252F2-3B3C-488E-BC6A-BD2544CED099Q33865523-AA248676-5032-426D-A28A-79B9E82E382CQ34062005-C15BADF6-0F3B-4D3E-9384-3C259B0B171FQ34357043-7162CAC2-C18F-4463-BB9A-90E5CEE13864Q35036231-C36CAE30-518F-4C32-83AF-BF7FF0A4C46EQ35187168-74737C0E-777D-4A29-AF01-84A523E1F864Q35204658-949513A0-FA3D-4DAA-8BE2-7094189B8C41Q35206236-FCF8AC26-22CA-4126-8740-0AA7CF99A8C5Q35206252-EE720CAB-1D29-4D66-96E8-93A14E8C7C27Q35210731-4180EF5B-B147-4D53-B91A-B6EF4D4343AAQ35210752-603CA7D0-74D7-4FA2-AEB8-A82C15BAFBD8Q35450056-BB21C3FE-1C10-4170-99C1-982B5275746AQ35603867-B2F8BF88-CBE5-4533-AC4C-5FFE103F664EQ35788894-FD7ABB3B-9D04-40A6-B3C7-80B70E59FF4FQ35815301-0426BB12-5390-47BE-B1D0-1A3B0A0B9A45Q35923672-17ED730A-DEB4-48F6-98EF-E161D1C8D483Q36129721-93D47F7C-4589-4417-AC4F-18725E3020B6Q36367401-FD0D3BB4-CD9D-487B-814B-3B891A24615EQ36493829-07D27629-16D1-4A84-8E6B-714D2E892B73Q36698172-03E16B0A-B95E-4863-B72A-CE46943602F9Q36893208-0CAC01F7-7B61-458E-B59F-B6CC102E0A9CQ36977704-41928122-4E48-4227-9920-54AF51CEE0F4Q37079461-F1783D7A-A2D5-40BE-A599-6E62291EE48BQ37186888-F7AF75DD-5178-4122-9A08-7C86018C52CDQ37264971-EE9BD586-78BF-43B4-96CD-1A44AB562103Q37278379-A0B2F38A-853C-44DF-A230-90DD395BA5ACQ37590984-0E50F9B3-0038-499D-B74C-0F20BCD86D8DQ38008052-9D734803-21B5-415F-AE6E-E3EFD0CFDDB7Q38211104-8A762265-B298-44B8-915D-624494879EDAQ38244843-29D85748-4860-4A91-A5F3-A070577243BEQ38583842-0798F0B1-C4D4-4EC9-BFBD-FD49B38134B2Q38763015-DED6525C-CCEE-48E2-9884-2156F734671AQ38779273-17179534-90CD-4D9F-9730-7BA597F27282
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
Terri S Armstrong
@en
Terri S Armstrong
@nl
type
label
Terri S Armstrong
@en
Terri S Armstrong
@nl
prefLabel
Terri S Armstrong
@en
Terri S Armstrong
@nl
P106
P31
P496
0000-0002-2414-0492